Patents by Inventor Rory Rohm

Rory Rohm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CEACAM5 ANTIBODIES, ANTIBODY-DRUG CONJUGATES AND METHODS OF USES THEREOF
    Publication number: 20250381291
    Abstract: The present invention relates to antibodies that bind to CEACAM5 and antibody-drug conjugates thereof. The present invention also relates to compositions and methods and uses of antibodies that specifically bind to CEACAM5 and antibody-drug conjugates thereof.
    Type: Application
    Filed: June 11, 2025
    Publication date: December 18, 2025
    Inventors: Travis Biechele, Amanda L. Blasius, Jamie Apperson Mitchell, Albina Nesterova, Rory Rohm
  • Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
    Patent number: 11191771
    Abstract: This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 7, 2021
    Assignee: Seagen Inc.
    Inventors: William Arthur, Travis Biechele, Rory Rohm, Robert Thurman
  • Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
    Patent number: 11027021
    Abstract: This invention relates to treatment of cancer using antibody drug conjugates that comprise PBD molecules in combination with Bcl-2 inhibitors.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: June 8, 2021
    Assignee: Seagen Inc.
    Inventors: William Arthur, Robert Thurman, Travis Biechele, Rory Rohm
  • COMBINATIONS OF PBD-BASED ANTIBODY DRUG CONJUGATES WITH FLT3 INHIBITORS
    Publication number: 20190262354
    Abstract: This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.
    Type: Application
    Filed: June 8, 2017
    Publication date: August 29, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: William Arthur, Travis Biechele, Rory Rohm, Robert Thurman
  • COMBINATIONS OF PBD-BASED ANTIBODY DRUG CONJUGATES WITH BCL-2 INHIBITORS
    Publication number: 20190076549
    Abstract: This invention relates to treatment of cancer using antibody drug conjugates that comprise PBD molecules in combination with Bcl-2 inhibitors.
    Type: Application
    Filed: March 15, 2017
    Publication date: March 14, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: William Arthur, Robert Thurman, Travis Biechele, Rory Rohm